Last reviewed · How we verify
Inhaled Aztreonam
At a glance
| Generic name | Inhaled Aztreonam |
|---|---|
| Sponsor | UCSF Benioff Children's Hospital Oakland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial (PHASE2)
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer (PHASE1)
- Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis (PHASE4)
- Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (PHASE3)
- Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas (PHASE4)
- Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Aztreonam CI brief — competitive landscape report
- Inhaled Aztreonam updates RSS · CI watch RSS
- UCSF Benioff Children's Hospital Oakland portfolio CI